 Chiasma, Inc. CHMA, a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration FDA approved MYCAPSSAoctreotide capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog SSA approved by the FDA and the first product approved by the FDA utilizing Chiasmas Transient Permeability Enhancer TPE technology. 